Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: Interim guidance

WHO

Update on recommendations on antiretroviral regimens for treating and preventing HIV infection: In 2016, WHO published the consolidated guidelines on the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and recommended tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) (or emtricitabine, FTC) + efavirenz (EFV) 600 mg as the preferred first-line antiretroviral therapy (ART) regimen for adults and adolescents. Since that time, scientific evidence and programmatic experience have accumulated on the use of dolutegravir (DTG) in both first- and second-line ART, including during pregnancy and tuberculosis co-treatment, and for children. In 2018, these guidelines were reviewed to provide updated guidance on preferred option for these populations which now include DTG and RAL, and updated recommendations on using ARV drugs for HIV post-exposure prophylaxis. Annex 3 links to the ARV dosing guidance for children, adolescents and adults.

Update on early infant diagnosis of HIV: Since 2010, WHO has been recommending that HIV virological testing be used to diagnose HIV infection among infants and children younger than 18 months and that ART be started without delay while a second specimen is collected to confirm the initial positive virological test result. Since that time, evidence has been reviewed and in light of reducing mother-to-child transmission rates and thus decreasing positive predictive values, an indeterminate range to support more accurate early infant diagnosis is recommended.

February 5, 2019
Year of publication
2018
Resource types
Guidelines and Policies
Tags
antiretroviral therapy (ART), ART regimens, first-line antiretroviral therapy, second-line ART, early infant diagnosis (EID), virological testing, treatment guidelines, PEP, post-exposure prophylaxis (PEP)

Similar Resources

The purpose of this guide is to provide a resource for clinicians on the ground who manage HIV and TB clients on a daily basis.

Timely access to antiretroviral treatment (ART) is vital to ensuring safe motherhood and reducing vertical transmission. Treatment guidance and programming has changed dramatically in recent years.

In this report, UNAIDS is announcing that 18.2 million people now have access to HIV treatment. The Fast-Track response is working. Increasing treatment coverage is reducing AIDS-related deaths among adults and children. But the life-cycle approach has to include more than just treatment.

This guide is one of a series of good practice guides, and contains information, strategies and resources to help HIV programmers implement HIV programming for adolescents.

Malawi, like other countries with a generalized HIV epidemic, is striving to reach the ambitious targets set by UNAIDS known as the three 90's for testing, provision of antiretroviral therapy and viral suppression.

To understand the uptake of HIV services by adolescent women, the authors conducted a retrospective analysis of patient-level data (2011–2013) on services for antenatal care (ANC) and prevention of mother-to-child transmission (PMTCT) in 36 facilities in 5 districts in Zimbabwe.

Option B+ for prevention of mother-to-child transmission (PMTCT) specifies treating all HIV-positive women with antiretroviral therapy (ART) regardless of CD4 count. This simplified approach enhances countries' capacity to reach national HIV targets and contribute to the global 90-90-90 goals.…

These guidelines are intended as an update to those published in the Southern African Journal of HIV Medicine in 2014 and the update on when to initiate antiretroviral therapy in 2015.

On the sidelines of the 2017 United Nations General Assembly, U.S. Secretary of State Rex Tillerson announced the new PEPFAR Strategy for Accelerating HIV/AIDS Epidemic Control (2017-2020).

Antiretroviral therapy (ART) that enables suppression of HIV replication has been successfully rolled out at large scale to HIV-positive patients in low-income and middle-income countries.